US federal appeals court refuses to rehear Mirapex patent case
This article was originally published in Scrip
Executive Summary
A US federal appeals court has denied Mylan Pharmaceuticals' petition to have all of the circuit judges rehear a case that had given a win to Boehringer Ingelheim in a patent infringement case for its Parkinson's disease treatment, Mirapex (pramipexole dihydrochloride).